Invivyd, Inc. Stock News

Invivyd, Inc. (IVVD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Invivyd is developing an experimental antibody treatment to prevent COVID-19 in immunocompromised patients. An estimated 9 million immunocompromised patients in the U.S. don't respond strongly enough

Invivyd (IVVD) reports positive initial data from the phase III CANOPY study on VYD222 for the prevention of symptomatic COVID-19. Stock shoots up on the news.

VYD222 produced high serum virus neutralizing antibody titer levels in immunocompromised participants Data supportive of an immunobridging approach to the EVADE study of adintrevimab Overall favorable

Invivyd, Inc. (NASDAQ:IVVD ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Corporate Participants Scott Young - SVP, Investor Relations and Corporate Communications Dave Hering - Chief

WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases

WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases

Investing in biotech stocks is not for the meek. Losses can be very large and occur very quickly.

Invivyd's (IVVD) shares rallied almost 18% over the past three months, owing to promising developments in its monoclonal antibody candidate, VYD222, designed to prevent symptomatic COVID-19 infection.

Invivyd, Inc. (NASDAQ:IVVD ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Gabriella Linville-Engler - Investor Relations Dave Hering - Chief Financial Officer Pete

WALTHAM, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases

WALTHAM, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases

Invivyd, Inc (NASDAQ:IVVD ) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Kyra Faircloth - Investor Relations Dave Hering - Chief Executive Officer Pete Schmidt - Chi

WALTHAM, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases

The stock price of Invivyd Inc (NASDAQ: IVVD) fell by 7.89% in the most recent trading session. This is why.